DYRK1B

Across TCGA pan-cancer cohorts, DYRK1B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of DYRK1B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where DYRK1B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DYRK1B is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

KIRC, LIHC, and KIRP are the cancer types where DYRK1B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DYRK1B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.621	<.001	10	view →
LIHC	Female	II,III,IV	+1.730	<.001	8	view →
KIRP	All	II,III,IV	+0.585	<.001	7	view →
BLCA	All	All	+0.980	.006	6	view →
HNSC	All	All	−0.716	.004	6	view →
BRCA	All	All	+0.268	.001	6	view →
CHOL	Female	All	+3.300	<.001	5	view →
PRAD	All	All	+0.401	<.001	2	view →
UCEC	All	All	+0.399	.039	2	view →
THCA	All	All	+0.177	.016	2	view →
LUAD	Female	All	−0.346	.011	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

DYRK1B–KIRC

Open the KIRC breakdown →